Skip to Main Content

Paper Details

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Eur J Cancer
0
2023
Apalutamide, androgen, apalutamide, bone lesions, bone-only metastases, mCSPC, metastatic castration-sensitive prostate cancer, oligometastases, oligometastatic disease, patients, polymetastases, prostate-specific antigen
Author NameAffiliation
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
Kim N Chi
Anders BjartellSkane University Hospital, Lund University
  • 1 - 3

Datasets

Release 1.2